Updated:
Fresenius Medical Care
Fresenius Medical Care spun out from the German healthcare group Fresenius SE in 1996, inheriting a dialysis business that already spanned manufacturing...
Fresenius Medical Care
Fresenius Medical Care spun out from the German healthcare group Fresenius SE in 1996, inheriting a dialysis business that already spanned manufacturing and clinical services. The firm listed publicly but remains anchored by the Else Kröner-Fresenius Foundation, a non-profit that is the Fresenius group's largest shareholder and inherits its proceeds — embedding a charitable purpose in the corporate DNA. Today the company treats roughly 345,000 patients across approximately 4,000 dialysis clinics globally (per the firm, 2024). Fresenius Medical Care deploys capital across two tightly linked segments: Care Delivery — the operation of outpatient and home dialysis centers — and Care Enablement — the production of hemodialysis machines, dialyzers, concentrates, and disposables. The company also maintains a health information technology subsidiary and a portfolio of vascular access and renal pharmacy services. Geographic exposure centers on the United States, which generates the majority of revenue, alongside major presences in China, Germany, and Latin America. Following years of operational drag from pandemic-era labor inflation and excess mortality in the dialysis population, the firm initiated a portfolio simplification in 2023, selling non-core assets and consolidating its legal structure. In April 2024 Fresenius Medical Care completed its conversion from a German AG partnership limited by shares (KGaA) to a standard stock corporation (AG), streamlining governance and capital markets appeal. The firm's structural differentiator is its closed-loop economics: it manufactures the equipment, owns the clinics, employs the clinical staff, and operates the pharmacy and lab services that support treatment. No other dialysis provider combines manufacturing at this scale with the global care-delivery footprint, creating a capital-allocation rhythm where demand for consumables from its own clinics provides a recurring, visible revenue base that funds development of next-generation devices.
General information
Firm type
Asset Manager
Year founded
1996
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Bad Homburg
Corporate office
Else-Kröner-Straße 1, 61352 Bad Homburg, Germany
Additional offices
Waltham, MA, United States
Principals
Helen Giza
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Fresenius Medical Care?
Fresenius Medical Care is an operating company, not a traditional fund; capital allocation is directed by CEO Helen Giza and the Management Board, with strategic oversight from the Supervisory Board. The Else Kröner-Fresenius Foundation, as the largest shareholder, exerts long-term influence on major structural decisions. Day-to-day deployment focuses on organic clinic growth, manufacturing capacity, and tuck-in acquisitions in renal care.
How is Fresenius Medical Care related to the Else Kröner-Fresenius Foundation?
The non-profit Else Kröner-Fresenius Foundation is the largest shareholder of Fresenius SE, which in turn is the majority stakeholder in Fresenius Medical Care. Historically, the foundation receives dividends that fund medical research and humanitarian projects. This structure means the firm's commercial success directly generates charitable capital.
What geographies drive Fresenius Medical Care's operations?
The United States accounts for the largest share of revenue and clinic count, with Fresenius Kidney Care operating across most states. China is a growing secondary market where the firm runs its own clinics and sells products to third-party hospitals. The company also has material clinical and manufacturing footprints in Germany, Latin America, and select Asia-Pacific countries.
Does Fresenius Medical Care own its dialysis-product manufacturing?
Yes. Through its Care Enablement segment, the firm manufactures hemodialysis machines, dialyzers, bloodlines, concentrates, and related disposables in its own facilities. These products supply both the firm's clinic network and external dialysis providers globally.
What structural changes occurred in 2023–2024?
During 2023, the firm sold non-strategic assets and began a portfolio simplification drive to improve margins. The most notable change came in April 2024 when shareholders approved converting the public company from a KGaA (partnership limited by shares) to an AG (stock corporation), eliminating a dual-board complexity that had previously slowed governance decisions (per the firm, April 2024).
What is the company's posture on home dialysis?
Fresenius Medical Care promotes home hemodialysis and peritoneal dialysis as a growing portion of its care delivery model, supported by its NxStage and Liberty cycler product lines. Home-based treatment expands the addressable patient pool while reducing per-treatment facility overhead. The company runs dedicated home-dialysis training and logistics programs in its major markets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: